-
Mashup Score: 11
Dr. Luis Raez, a thoracic oncologist and director of Memorial Cancer Institute in Miami, emphasizes the significance of diversity, equity, and inclusion (DEI) within the IASLC. He urges members to engage in the DEI survey, playing a pivotal role in molding a more inclusive future.
Source: voicesoftheiaslc.gv-one.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Regulatory News for April 24, 2024 - ILCN.org (ILCN/WCLC) - 7 day(s) ago
US FDA grants accelerated approval of HER2-targeting antibody drug conjugate; China accepts supplemental new drug application for savolitinib.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The IASLC seeks new and returning applicants to serve as volunteer members of the Staging and Prognostic Factors Group (SPFG) for the 10th edition of the Staging Project: Lung Cancer, Mesothelioma, and Thoracic Malignancies. The SPFG oversees data collection and analysis for the IASLC Staging Project and publishes recommendations for improvements to the TNM classification system. Please read on for more information about responsibilities of SPFG members and instructions for how to apply. Members of the
Source: iaslc.secure-platform.comCategories: General Medicine News, Onc News and JournalsTweet-
Apply Now for the IASLC 10th Edition Staging & Prognostic Factors Group! We welcome applications from multidisciplinary #IASLC members who have an interest in the field. Applications are open from 5/6 - 6/21. Let's work together to advance the field! https://t.co/xHSP2nQpCz #LCSM https://t.co/qAS29ar8lx
-
-
Mashup Score: 42024 IASLC CT Screening Symposium | IASLC - 11 day(s) ago
The CT Screening Symposium is a 1-day, immersive, in-person event being featured at WCLC 2024 focused on lung cancer screening technologies and best practices. …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
Register Now for the 2024 CT Screening Symposium: Forefront Advances in Lung Cancer Screening! A premier event featured @ #WCLC24, taking place in San Diego, CA, Sept. 7, & dedicated to advancing knowledge/practices in #lungcancer screening. https://t.co/ExsyHGeO44 #CTSS24 #LCSM https://t.co/n4gd5ThU2x
-
-
Mashup Score: 40Registration - WCLC 2024 - 11 day(s) ago
Get ready to dive into cutting-edge research, connect with professionals worldwide, and hear from the best in the field. WCLC 2024 promises to be a
Source: wclc2024.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
Early Registration for #WCLC24 is now open, w/an exceptional program that encapsulates the spirit of #IASLC & its members. Join the IASLC 50yr Anniversary celebrations! We look forward to welcoming you to an inspiring, educational & enjoyable program:https://t.co/Teoo6K0KxW #LCSM https://t.co/4AlvXKo8qC
-
-
Mashup Score: 14Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm? - ILCN.org (ILCN/WCLC) - 11 day(s) ago
In a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
Dr. Narjust Florez, Lung Cancer Considered Host, encourages members to participate in the first IASLC Global Membership Survey on Inclusivity. The 5-minute survey, is available in multiple languages and aims to understand the unique needs of each of our regions and those members. The data collected will be used to improve the organization’s diversity, equity, and inclusion efforts.
Source: voicesoftheiaslc.gv-one.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination - ILCN.org (ILCN/WCLC) - 12 day(s) ago
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Dr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage III NSCLC during the 2024 European Lung Cancer Congress.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 31KRAS in NSCLC: Beyond G12C | IASLC - 13 day(s) ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, focusing on non-G12C mutations. KRAS mutations …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
KRAS mutations are common in #lungcancer, & while there are multiple approved/active KRAS inhibitors, they are specifically for the G12C mutation. @StephenVLiu discusses KRAS mutant #NSCLC w/focus on non-G12C mutations w/Dr. Veluswamy & @MarianaBrandao0: https://t.co/iI5ORV5u8l https://t.co/RPxBJbqO5a
-
Watch @LuisRaezMD urge members of the #IASLC to participate in the IASLC Global Member Survey on Inclusivity, contributing to the development of a more inclusive future. Watch Now: https://t.co/BNWCeKYpuY #LCSM https://t.co/mEEkxs1Jv8